Diabetic Foot Ulcers – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Diabetic Foot Ulcers – Pipeline Review, H2 2017’, provides an overview of the Diabetic Foot Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers

The report reviews pipeline therapeutics for Diabetic Foot Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Foot Ulcers therapeutics and enlists all their major and minor projects

The report assesses Diabetic Foot Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ANP Technologies Inc

Anterogen Co Ltd

Boston Therapeutics Inc

CardioVascular BioTherapeutics Inc

Celgene Corp

Chrysalis BioTherapeutics Inc

CytoTools AG

Energenesis Biomedical Co Ltd

EyeGene Inc

FirstString Research Inc

Genentech Inc

GlaxoSmithKline Plc

Human Stem Cells Institute

Izun Pharmaceuticals Corp

Lakewood-Amedex Inc

MediWound Ltd

Oneness Biotech Co Ltd

Osiris Therapeutics Inc

Pherecydes Pharma SA

ProMetic Life Sciences Inc

Serodus ASA

Stempeutics Research Pvt Ltd

Stratatech Corp

TechnoPhage SA

Topadur Pharma AG

USV Pvt Ltd

viDA Therapeutics Inc

ViroMed Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Diabetic Foot Ulcers - Overview 5

Diabetic Foot Ulcers - Therapeutics Development 6

Diabetic Foot Ulcers - Therapeutics Assessment 16

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 24

Diabetic Foot Ulcers - Drug Profiles 36

Diabetic Foot Ulcers - Dormant Projects 112

Diabetic Foot Ulcers - Discontinued Products 115

Diabetic Foot Ulcers - Product Development Milestones 116

Appendix 125

List of Tables

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H2 2017 11

Number of Products under Development by Companies, H2 2017 13

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15

Number of Products under Development by Universities/Institutes, H2 2017 16

Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19

Products under Development by Universities/Institutes, H2 2017 20

Number of Products by Stage and Target, H2 2017 22

Number of Products by Stage and Mechanism of Action, H2 2017 24

Number of Products by Stage and Route of Administration, H2 2017 26

Number of Products by Stage and Molecule Type, H2 2017 28

Diabetic Foot Ulcers – Pipeline by ANP Technologies Inc, H2 2017 29

Diabetic Foot Ulcers – Pipeline by Anterogen Co Ltd, H2 2017 29

Diabetic Foot Ulcers – Pipeline by Boston Therapeutics Inc, H2 2017 30

Diabetic Foot Ulcers – Pipeline by CardioVascular BioTherapeutics Inc, H2 2017 30

Diabetic Foot Ulcers – Pipeline by Celgene Corp, H2 2017 30

Diabetic Foot Ulcers – Pipeline by Chrysalis BioTherapeutics Inc, H2 2017 31

Diabetic Foot Ulcers – Pipeline by CytoTools AG, H2 2017 31

Diabetic Foot Ulcers – Pipeline by Energenesis Biomedical Co Ltd, H2 2017 32

Diabetic Foot Ulcers – Pipeline by EyeGene Inc, H2 2017 32

Diabetic Foot Ulcers – Pipeline by FirstString Research Inc, H2 2017 32

Diabetic Foot Ulcers – Pipeline by Genentech Inc, H2 2017 33

Diabetic Foot Ulcers – Pipeline by GlaxoSmithKline Plc, H2 2017 33

Diabetic Foot Ulcers – Pipeline by Human Stem Cells Institute, H2 2017 34

Diabetic Foot Ulcers – Pipeline by Izun Pharmaceuticals Corp, H2 2017 34

Diabetic Foot Ulcers – Pipeline by Lakewood-Amedex Inc, H2 2017 35

Diabetic Foot Ulcers – Pipeline by MediWound Ltd, H2 2017 35

Diabetic Foot Ulcers – Pipeline by Oneness Biotech Co Ltd, H2 2017 36

Diabetic Foot Ulcers – Pipeline by Osiris Therapeutics Inc, H2 2017 36

Diabetic Foot Ulcers – Pipeline by Pherecydes Pharma SA, H2 2017 36

Diabetic Foot Ulcers – Pipeline by ProMetic Life Sciences Inc, H2 2017 37

Diabetic Foot Ulcers – Pipeline by Serodus ASA, H2 2017 37

Diabetic Foot Ulcers – Pipeline by Stempeutics Research Pvt Ltd, H2 2017 38

Diabetic Foot Ulcers – Pipeline by Stratatech Corp, H2 2017 38

Diabetic Foot Ulcers – Pipeline by TechnoPhage SA, H2 2017 39

Diabetic Foot Ulcers – Pipeline by Topadur Pharma AG, H2 2017 39

Diabetic Foot Ulcers – Pipeline by USV Pvt Ltd, H2 2017 39

Diabetic Foot Ulcers – Pipeline by viDA Therapeutics Inc, H2 2017 40

Diabetic Foot Ulcers – Pipeline by ViroMed Co Ltd, H2 2017 40

Diabetic Foot Ulcers – Dormant Projects, H2 2017 117

Diabetic Foot Ulcers – Dormant Projects, H2 2017 (Contd..1), H2 2017 118

Diabetic Foot Ulcers – Dormant Projects, H2 2017 (Contd..2), H2 2017 119

Diabetic Foot Ulcers – Discontinued Products, H2 2017 120

List of Figures

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Number of Products by Top 10 Targets, H2 2017 21

Number of Products by Stage and Top 10 Targets, H2 2017 21

Number of Products by Top 10 Mechanism of Actions, H2 2017 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 25

Number of Products by Stage and Routes of Administration, H2 2017 25

Number of Products by Top 10 Molecule Types, H2 2017 27

Number of Products by Stage and Top 10 Molecule Types, H2 2017 27

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports